Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.00 – $0.01
100% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $79.4M | $16.1M | $12.8M | $13.4M | $13.4M | $17.0M | $23.3M | $29.3M |
| Cost of revenue | $33.0M | $3.0M | $14.4M | $11.6M | $14.1M | $16.2M | $3.1M | $10.4M |
| Gross profit | $46.4M | $13.2M | −$1.6M | $1.8M | −$765.0K | $842.0K | $20.2M | $18.9M |
| Gross margin | 58.4% | 81.6% | -12.8% | 13.2% | -5.7% | 4.9% | 86.6% | 64.5% |
| R&D | $2.8M | $2.0M | $107.0K | $162.0K | $276.0K | $617.0K | $4.5M | $3.8M |
| Operating income | −$3.5M | −$7.0M | −$7.2M | −$5.0M | −$6.6M | −$11.8M | −$9.0M | −$4.5M |
| EBITDA | −$1.5M | −$4.2M | −$5.7M | −$3.5M | −$7.9M | −$9.5M | −$6.0M | −$6.7M |
| Net income | −$5.1M | −$6.7M | −$7.0M | −$4.4M | −$7.5M | −$15.3M | −$8.8M | −$9.1M |
| Net margin | -6.4% | -41.3% | -54.7% | -32.5% | -56.0% | -89.8% | -37.7% | -31.0% |
| EPS (diluted) | -0.04 | -0.05 | -0.05 | -0.03 | -0.05 | -0.10 | -0.04 | -0.04 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $33M | $-0.02 | $-0.02–$-0.02 | 1 |
| 2027 | $42M | $-0.00 | $-0.00–$-0.00 | 1 |
| 2028 | $51M | $0.01 | $0.01–$0.01 | 1 |
Forward consensus · source: Financial Modeling Prep
NOVA EYE MED LTD
No one on the platform currently holds ELXMF.
No tracked institution reports a position in ELXMF as of their last filing.
No one on the platform has traded ELXMF yet.
| $35M |
| — |
| NXSCFNext Science Limited | $0.00 | -93.75% | $292625 | — |
| PETVPetVivo Holdings, Inc. | $0.88 | +3.53% | $24M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.